1. Home
  2. EVOK vs LCFY Comparison

EVOK vs LCFY Comparison

Compare EVOK & LCFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EVOK
  • LCFY
  • Stock Information
  • Founded
  • EVOK 2007
  • LCFY 2009
  • Country
  • EVOK United States
  • LCFY Australia
  • Employees
  • EVOK N/A
  • LCFY N/A
  • Industry
  • EVOK Biotechnology: Pharmaceutical Preparations
  • LCFY
  • Sector
  • EVOK Health Care
  • LCFY
  • Exchange
  • EVOK Nasdaq
  • LCFY Nasdaq
  • Market Cap
  • EVOK 7.1M
  • LCFY 7.3M
  • IPO Year
  • EVOK 2013
  • LCFY 2022
  • Fundamental
  • Price
  • EVOK $4.81
  • LCFY $7.42
  • Analyst Decision
  • EVOK
  • LCFY
  • Analyst Count
  • EVOK 0
  • LCFY 0
  • Target Price
  • EVOK N/A
  • LCFY N/A
  • AVG Volume (30 Days)
  • EVOK 10.0K
  • LCFY 24.4K
  • Earning Date
  • EVOK 03-13-2025
  • LCFY 04-01-2025
  • Dividend Yield
  • EVOK N/A
  • LCFY N/A
  • EPS Growth
  • EVOK N/A
  • LCFY N/A
  • EPS
  • EVOK N/A
  • LCFY N/A
  • Revenue
  • EVOK $8,617,036.00
  • LCFY $2,668,385.00
  • Revenue This Year
  • EVOK $97.35
  • LCFY N/A
  • Revenue Next Year
  • EVOK $99.52
  • LCFY N/A
  • P/E Ratio
  • EVOK N/A
  • LCFY N/A
  • Revenue Growth
  • EVOK 100.35
  • LCFY N/A
  • 52 Week Low
  • EVOK $3.54
  • LCFY $2.20
  • 52 Week High
  • EVOK $12.32
  • LCFY $11.23
  • Technical
  • Relative Strength Index (RSI)
  • EVOK 59.77
  • LCFY 43.49
  • Support Level
  • EVOK $4.68
  • LCFY $7.10
  • Resistance Level
  • EVOK $4.94
  • LCFY $9.39
  • Average True Range (ATR)
  • EVOK 0.28
  • LCFY 0.64
  • MACD
  • EVOK 0.06
  • LCFY -0.15
  • Stochastic Oscillator
  • EVOK 73.58
  • LCFY 8.16

About EVOK Evoke Pharma Inc.

Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.

About LCFY Locafy Limited

Locafy Ltd is focused on commercializing its Software as a Service (SaaS) online publishing technology platform. Its platform enables the ability to publish almost any type of content to almost any device that uses a web browser to display web content. The firm has three operating segments: the Publishing segment, the Reseller segment, and the Channel sales segment. It derives a majority of its revenue from Australia and New Zealand.

Share on Social Networks: